12. Weekly Data
Progress
Data
Data
LaunchPad Central Software
Hypotheses
Experiments
Data
Evidence-based Methodology (NSF I-Corps/Lean LaunchPad)
Business Model
Canvas
+
Customer
Development
Lean Startup
+
Agile Engineering
33. Remote monitoring device to prevent
severe flares in pediatric asthmatics
Total interviews: 117
Lessons Learned
December 10, 2013
Basil Ayish
Noel Jee
Clare Pak
CharviShetty
Jingwei Zhang
34.
35.
36. DEV. 2:
Michael Harrison
Michael Danty
Dillon Kwiat
Elisabeth Leeflang
Matt Clark
December 10, 2013
FINAL PRESENTATION
Vision: A new way to create a magnetic
compression anastomosis with improved
outcomes.
Interviews completed: 90
38. INVESTMENT READINESS LEVEL
IRL 6
Plausible exit
Cash to 1st inflection point
Unit economics validated
Reimbursement / other revenue
Regulatory path certainty & difficulty
IP freedom to operate & ability to block
Attractive solution & ID of MVP
Compelling clinical need + large market
Effective team?
MAGNAMOSIS, Inc.
38
39. Total
Interviews: 88
Vantage Realized is building a wheelchair attachment that increases mobility and
reduces joint damage for manual wheelchair users.
40. Final Canvas
Strong
emphasis on
protective IP
End users don’t rely
on magazines for new
product information.
The wheelchair
manufacturers are
the best way to sell
through DME or
online retailers.
Manufacturing
cost ~$6
Most likely asset sale vs.
licensing
42. Vitruvian
Preventing Hernias Before They Happen
December 10, 2013
Mentor: Julie Cherrington
Team:
Cindy Chang, PhD
Hobart W. Harris, MD, MPH
David M. Young, MD
Customer Interviews : 74
47. INVESTOR READINESS
“Proof of Relevance” Path to Revenue Fully Articulated
High Fidelity MVP
Business Case Defined
“Left Side of the Canvas”
Build KOL network
Deeper IP review and strategy
Due diligence on partners
Deeper cost analysis to each data point
Team talent gaps identified
“Right Side of the Canvas”
Product Market Fit
Problem/Solution Validation
Low Fidelity MVP
First Pass Canvas
IRL6
50. Senior customer endorsement
Operational plan validated
Talent recruited
IP strategy and KOL network
“Proof of Relevance” defined
Timeline and cost to data points
Strategic fit in portfolio validated
Technology confirmed
First pass canvas
51. “God is not on the side of the big arsenals,
but on the side of those who shoot best.”
Voltaire
Notes de l'éditeur
In this iteration, we learned that asthmatics were further subdivided into affluent and lower socioeconomic brackets.
In terms of investment readiness, we are fairly certain that we have a strong and capable team. We also believe that there is a compelling clinical need here, and if we are able to expand into the larger respiratory health market including monitoring in polluted areas or capturing adult asthma and COPD segments, we would also have a large enough market to sustain a company.
Our company is Vitruvian and we are developing a product to prevent incisional hernias. Introduce the whole team…
…we discovered that no one really owns this problem, not even some surgeons.
